Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection

NCT01492426 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

605

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: Daclatasvir
DRUG: Telaprevir
DRUG: Peginterferon alfa-2a
DRUG: Ribavirin

Sponsor

Bristol-Myers Squibb